Research advances of factors and mechanisms for therapeutic efficacy of rituximab for primary membranous nephropathy
Primary membranous nephropathy （PMN） is a kidney-specific autoimmune disease mediated by autoantibodies. Although rituximab （RTX） has been widely applied as a first-line treatment for PMN, 20%-40% patients are non-responsive to RTX. High disease activity, severe renal lesions and low RTX bioavailabi...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Editorial Department of Journal of Clinical Nephrology,
2024-09-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |